Result of AGM

Ovoca Bio PLC

01 December 2023

 

Ovoca Bio plc

("Ovoca" or the "Company")

Result of AGM

Dublin, Ireland, December 1, 2023 - Ovoca Bio, a biopharmaceutical company with a focus on women's health, announces that all resolutions proposed at the Company's Annual General Meeting held yesterday were passed. Voting on all resolutions was conducted by poll and the results are available on the Company's website at www.ovocabio.com.

The full text of the approved resolutions can be found in the Notice of the Annual General Meeting. The Notice is also available to view and download from the Company's website.

End

For further information:

Ovoca Bio plc

Kirill Golovanov (Chief Executive)

Tel [phone]

[e-mail]

Davy (Nominated Adviser, Euronext Growth Listing Sponsor and Broker)

Ivan Murphy / Daragh O'Reilly

Tel: [phone]

About Ovoca Bio

Ovoca Bio is a European-based biopharmaceutical company with a focus on women's health. The Company is currently developing Orenetide (BP-101), a novel synthetic peptide administered through a nasal spray as a novel treatment for women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack or loss of sexual desire affecting an estimated ~4 million premenopausal women in the US alone.

 

END